What Sell-Off? Biotechs Cruise: CLVS, SGEN
Stocks in Sharp Sell-Off on Potential FED Rate Increase and Strong Dollar Deflation is Still Lurking S&P Down 1.7%, NASDAQ down 1.67% Biotech stocks avoided the severe sell-off today apparently immune to the strong dollar, flat earnings growth and FED interest rate concerns. Although life...
Biotechs Roaring Back: Do They Sense A Deal? Update -1 ABBV/PCYC
Whoa! $261.25 And the winner is Abbvie (ABBV) for $21B! Pharmacyclics Buzz Is Back Biotech stocks covered the green screen today, despite a listless general market, driven by deal talk regarding Pharmacyclics (PCYC). Q4 2014 sales of their potential blockbuster drug Imbruvica for chronic...
Mid Cap Emerging Biopharmaceutical Companies: Valuations Do Matter for M&A
Update-1… On Onyx $10.4B Buyout By Amgen (AMGN) Valuation Models for Biopharma Stocks -M&A Update In October 2013 we compared emerging biotech stocks after the acquisition of Onyx Pharmaceuticals by Amgen (AMGN). Now that rumors are “out there” for the acquisition of...
SierraSnow Blog 2/27-3/3/15…. More Snowpack
More snow coming this weekend: Jet Stream in Place earth :: an animated map of global wind, weather, and ocean conditions National Maps – NOAA’s National Weather Service 814prcp.new.gif 719×759 pixels Colder wetter bringing 12 in.+ Mammoth Lakes Weather brought to you by Howard...
Rayno Biopharmaceutical Stocks: PCYC Buzz Drive Biotechs Higher… Update-1
2/27 Friday After a big February biotechs turned red today with major ETFs off about 1%. In light of recent M&A talk about Pharmacyclics, Inc. (PCYC) at Market Cap of $16.6B we will look at other top Mid-Cap biopharmaceutical stocks for comparison to our motif below: ALNY, BMRN, INCY, MDVN,...